cblE type of homocystinuria due to methionine synthase reductase deficiency: functional correction by minigene expression.
The cblE type of homocystinuria is a rare autosomal recessive disorder caused by impaired reductive activation of methionine synthase. Although earlier biochemical studies proposed that the methionine synthase enzyme might be activated by two different reducing systems, mutations were reported in only the methionine synthase reductase gene (MTRR) in cblE patients. The pathogenicity of MTRR mutations, however, has not yet been tested functionally. We report on nine patients of European origin affected by the cblE type of homocystinuria. They presented between 2 weeks and 3 years of age (median age 4 weeks) with anemia, which was macrocytic in only three patients, and with neurological involvement in all but two cases. Bone marrow examination performed in seven patients showed megaloblastic changes in all but one of them. All patients exhibited moderate to severe hyperhomocysteinemia (median plasma total homocysteine [Hcy] 92 mumol/L, range 44-169), while clearly reduced methionine was observed only in four cases. Pathogenic mutations were identified in both parental alleles of the MTRR gene in all patients. Five known (c.903+469T>C, c.1361C>T, c.1459G>A, c.1557-4_1557+3del7, and c.1622_1623dupTA) and three novel mutations (c.7A>T, c.1573C>T, and c.1953-6_1953-2del5) were detected. Importantly, transfection of fibroblasts of cblE patients with a wild-type MTRR minigene expression construct resulted in a significant approximately four-fold increase of methionine synthesis, indicating correction of the enzyme defect. Our study shows a link between a milder predominantly hematological presentation and homozygosity for the c.1361C>T mutation, but no other obvious genotype-phenotype correlation. The identification of mutations in the MTRR gene, together with restoration of methionine synthesis following MTRR minigene expression in cblE cells confirms that this disease is caused by defects in the MTRR gene.
Zavadáková
Petra
P
Institute of Inherited Metabolic Diseases, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Fowler
Brian
B
Suormala
Terttu
T
Novotna
Zorka
Z
Mueller
Peter
P
Hennermann
Julia B
JB
Zeman
Jirí
J
Vilaseca
M Antonia
MA
Vilarinho
Laura
L
Gutsche
Sven
S
Wilichowski
Ekkehard
E
Horneff
Gerd
G
Kozich
Viktor
V
D013766:5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase / Q000172:deficiency*; D019943:Amino Acid Substitution; D001622:Betaine / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D002461:Cell Line, Transformed / Q000201:enzymology / Q000473:pathology; D018389:Codon, Nonsense; D004252:DNA Mutational Analysis; D005287:Ferredoxin-NADP Reductase / Q000172:deficiency* / Q000235:genetics; D005347:Fibroblasts / Q000201:enzymology / Q000473:pathology; D005492:Folic Acid / Q000627:therapeutic use; D005813:Genes, Synthetic; D005816:Genetic Complementation Test; D015316:Genetic Therapy; D006239:Haplotypes / Q000235:genetics; D006710:Homocysteine / Q000097:blood; D006712:Homocystinuria / Q000097:blood / Q000145:classification / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D006801:Humans; D006879:Hydroxocobalamin / Q000627:therapeutic use; D020125:Mutation, Missense; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D011993:Recombinant Fusion Proteins / Q000502:physiology; D017384:Sequence Deletion; D014162:Transfection; D044465:White People / Q000235:genetics
D018389:Codon, Nonsense; D011993:Recombinant Fusion Proteins; D006710:Homocysteine; D001622:Betaine; D005492:Folic Acid; C111241:methionine synthase reductase; D005287:Ferredoxin-NADP Reductase; D013766:5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; D006879:Hydroxocobalamin